Format
Sort by
Items per page

Send to

Choose Destination

Best matches for disease progression AND huntington disease:

Search results

Items: 1 to 20 of 1374

1.

Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma.

Luo H, Quan X, Song XY, Zhang L, Yin Y, He Q, Cai S, Li S, Zeng J, Zhang Q, Gao Y, Yu S.

Oncotarget. 2017 Sep 30;8(54):92522-92535. doi: 10.18632/oncotarget.21439. eCollection 2017 Nov 3.

2.

Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.

Connor B.

Stem Cells. 2017 Nov 26. doi: 10.1002/stem.2747. [Epub ahead of print] Review.

PMID:
29178352
3.

Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.

Sharma DL, Lakhani HV, Klug RL, Snoad B, El-Hamdani R, Shapiro JI, Sodhi K.

J Clin Cell Immunol. 2017 Oct;8(5). pii: 523. doi: 10.4172/2155-9899.1000523. Epub 2017 Sep 29.

4.

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease.

Di Pardo A, Castaldo S, Capocci L, Amico E, Vittorio M.

J Vis Exp. 2017 Nov 8;(129). doi: 10.3791/56389.

PMID:
29155766
5.

Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models.

Yu M, Fu Y, Liang Y, Song H, Yao Y, Wu P, Yao Y, Pan Y, Wen X, Ma L, Hexige S, Ding Y, Luo S, Lu B.

Cell Res. 2017 Dec;27(12):1441-1465. doi: 10.1038/cr.2017.113. Epub 2017 Oct 13.

6.

Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss.

Maiese K.

Curr Neurovasc Res. 2017 Nov 15. doi: 10.2174/1567202614666171116102911. [Epub ahead of print]

PMID:
29149835
7.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

PMID:
29142089
8.

HIPK3 modulates autophagy and HTT protein levels in neuronal and mouse models of Huntington disease.

Fu Y, Sun X, Lu B.

Autophagy. 2017 Nov 13:1-6. doi: 10.1080/15548627.2017.1393130. [Epub ahead of print]

PMID:
29130397
9.

Glycocalyx in Atherosclerosis-Relevant Endothelium Function and as a Therapeutic Target.

Mitra R, O'Neil GL, Harding IC, Cheng MJ, Mensah SA, Ebong EE.

Curr Atheroscler Rep. 2017 Nov 10;19(12):63. doi: 10.1007/s11883-017-0691-9. Review.

10.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

PMID:
28975278
11.

Preclinical motor manifestations of Huntington disease.

McGarry A, Biglan KM.

Handb Clin Neurol. 2017;144:93-98. doi: 10.1016/B978-0-12-801893-4.00007-9.

PMID:
28947128
12.

The diagnosis and natural history of Huntington disease.

Pagan F, Torres-Yaghi Y, Altshuler M.

Handb Clin Neurol. 2017;144:63-67. doi: 10.1016/B978-0-12-801893-4.00005-5.

PMID:
28947126
13.

Functional imaging in Huntington disease.

Niethammer M, Eidelberg D.

Handb Clin Neurol. 2017;144:263-287. doi: 10.1016/B978-0-12-801893-4.00021-3.

PMID:
28947122
14.

The role of rehabilitation therapy in Huntington disease.

Quinn L, Busse M.

Handb Clin Neurol. 2017;144:151-165. doi: 10.1016/B978-0-12-801893-4.00013-4.

PMID:
28947114
15.

Medical management of motor manifestations of Huntington disease.

McCusker EA, Loy CT.

Handb Clin Neurol. 2017;144:141-150. doi: 10.1016/B978-0-12-801893-4.00012-2.

PMID:
28947112
16.

Medical treatment of behavioral manifestations of Huntington disease.

van Duijn E.

Handb Clin Neurol. 2017;144:129-139. doi: 10.1016/B978-0-12-801893-4.00011-0.

PMID:
28947111
17.

Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.

Cabanas M, Bassil F, Mons N, Garret M, Cho YH.

PLoS One. 2017 Sep 21;12(9):e0184580. doi: 10.1371/journal.pone.0184580. eCollection 2017.

18.

Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial.

Sudfeld CR, Manji KP, Duggan CP, Aboud S, Muhihi A, Sando DM, Al-Beity FMA, Wang M, Fawzi WW.

Trials. 2017 Sep 4;18(1):411. doi: 10.1186/s13063-017-2157-3.

19.

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.

Liu X, Qin S, Wang Z, Xu J, Xiong J, Bai Y, Wang Z, Yang Y, Sun G, Wang L, Zheng L, Xu N, Cheng Y, Guo W, Yu H, Liu T, Lagiou P, Li J.

J Hematol Oncol. 2017 Sep 5;10(1):153. doi: 10.1186/s13045-017-0521-0.

20.

Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.

Katz H, Wassie E, Alsharedi M.

Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8. Review.

PMID:
28864844

Supplemental Content

Loading ...
Support Center